281 related articles for article (PubMed ID: 33348190)
1. Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare population.
Guo JD; Hlavacek P; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
Thromb Res; 2021 Feb; 198():163-170. PubMed ID: 33348190
[TBL] [Abstract][Full Text] [Related]
2. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
[No Abstract] [Full Text] [Related]
3. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L
J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status.
Cohen AT; Sah J; Dhamane AD; Lee T; Rosenblatt L; Hlavacek P; Emir B; Keshishian A; Yuce H; Luo X
Adv Ther; 2021 Nov; 38(11):5519-5533. PubMed ID: 34570310
[TBL] [Abstract][Full Text] [Related]
5. Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses.
Weycker D; Wygant GD; Guo JD; Lee T; Luo X; Rosenblatt L; Mardekian J; Atwood M; Hanau A; Cohen AT
Blood Adv; 2020 Jan; 4(2):432-439. PubMed ID: 31990332
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.
Weycker D; Li X; Wygant GD; Lee T; Hamilton M; Luo X; Vo L; Mardekian J; Pan X; Burns L; Atwood M; Hanau A; Cohen AT
Thromb Haemost; 2018 Nov; 118(11):1951-1961. PubMed ID: 30357780
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences.
Cohen AT; Sah J; Dhamane AD; Hines DM; Lee T; Rosenblatt L; Emir B; Keshishian A; Yuce H; Luo X
Adv Ther; 2023 Apr; 40(4):1705-1735. PubMed ID: 36811795
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.
Dawwas GK; Smith SM; Dietrich E; Lo-Ciganic WH; Park H
Am J Health Syst Pharm; 2020 Jan; 77(3):188-195. PubMed ID: 31974557
[TBL] [Abstract][Full Text] [Related]
9. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis.
Cohen A; Keshishian A; Lee T; Wygant G; Rosenblatt L; Hlavacek P; Mardekian J; Wiederkehr D; Sah J; Luo X
Thromb Haemost; 2021 Mar; 121(3):383-395. PubMed ID: 33171521
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism.
Park H; Kang HR; Huang PL; Lo-Ciganic WH; DeRemer CE; Wilson D; Dietrich EA
Clin Transl Sci; 2023 Jan; 16(1):128-139. PubMed ID: 36200137
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease.
Cohen AT; Sah J; Dhamane AD; Lee T; Rosenblatt L; Hlavacek P; Emir B; Delinger R; Yuce H; Luo X
Thromb Haemost; 2022 Jun; 122(6):926-938. PubMed ID: 34963185
[TBL] [Abstract][Full Text] [Related]
13. Apixaban: A Review in Venous Thromboembolism.
Greig SL; Garnock-Jones KP
Drugs; 2016 Oct; 76(15):1493-1504. PubMed ID: 27653758
[TBL] [Abstract][Full Text] [Related]
14. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial.
Bleker SM; Cohen AT; Büller HR; Agnelli G; Gallus AS; Raskob GE; Weitz JI; Curto M; Sisson M; Middeldorp S
Thromb Haemost; 2016 Nov; 116(6):1159-1164. PubMed ID: 27583312
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding.
Cohen AT; Sah J; Dhamane AD; Lee T; Rosenblatt L; Hlavacek P; Emir B; Keshishian A; Yuce H; Luo X
PLoS One; 2022; 17(9):e0274969. PubMed ID: 36149864
[TBL] [Abstract][Full Text] [Related]
16. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
Brekelmans MP; Scheres LJ; Bleker SM; Hutten BA; Timmermans A; Büller HR; Middeldorp S
Thromb Haemost; 2017 Apr; 117(4):809-815. PubMed ID: 28180233
[TBL] [Abstract][Full Text] [Related]
17. Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity.
Crouch A; Ng TH; Kelley D; Knight T; Edwin S; ; Giuliano C
Pharmacotherapy; 2022 Feb; 42(2):119-133. PubMed ID: 34904263
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY.
Cohen AT; Pan S; Byon W; Ilyas BS; Taylor T; Lee TC
Adv Ther; 2021 Jun; 38(6):3003-3018. PubMed ID: 33890242
[TBL] [Abstract][Full Text] [Related]
19. Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end-stage kidney disease: A national cohort study.
Ellenbogen MI; Ardeshirrouhanifard S; Segal JB; Streiff MB; Deitelzweig SB; Brotman DJ
J Hosp Med; 2022 Oct; 17(10):809-818. PubMed ID: 35929542
[TBL] [Abstract][Full Text] [Related]
20. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
